相似文献
1
Cancer drugs: high price, uncertain value.
BMJ. 2017 Oct 4;359:j4543. doi: 10.1136/bmj.j4543.
2
The high price of progress.
Nat Rev Clin Oncol. 2017 Feb 20;14(3):129. doi: 10.1038/nrclinonc.2017.24.
3
Health policy: Putting a price on cancer.
Nat Rev Clin Oncol. 2016 Mar;13(3):137-8. doi: 10.1038/nrclinonc.2016.12. Epub 2016 Feb 9.
4
Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djx173.
5
Roche responds to the 'Herceptin or deception' article.
N Z Med J. 2006 Jul 7;119(1237):U2069; author reply U2069.
6
Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Ann Oncol. 2017 May 1;28(5):1111-1116. doi: 10.1093/annonc/mdx053.
7
Running short.
Minn Med. 2011 Oct;94(10):8-10.
8
NICE, the NHS, and Cancer Drugs.
JAMA. 2018 Feb 27;319(8):767-768. doi: 10.1001/jama.2017.20552.
9
Cancer Drugs Fund of minimal benefit.
Lancet Oncol. 2017 Jun;18(6):e305. doi: 10.1016/S1470-2045(17)30322-4. Epub 2017 May 5.
10
Approvals in 2016: questioning the clinical benefit of anticancer therapies.
Nat Rev Clin Oncol. 2017 Feb 20;14(3):135-136. doi: 10.1038/nrclinonc.2017.18.
引用本文的文献
1
Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability.
BioDrugs. 2025 Aug 8. doi: 10.1007/s40259-025-00732-2.
2
Anticancer activity of quantum size carbon dots: opportunities and challenges.
Discov Nano. 2024 Aug 5;19(1):122. doi: 10.1186/s11671-024-04069-7.
3
The need for a change in medical research thinking. Eco-systemic research frames are better suited to explore patterned disease behaviors.
Front Med (Lausanne). 2024 Jun 3;11:1377356. doi: 10.3389/fmed.2024.1377356. eCollection 2024.
4
The lack of head-to-head randomised trials and the consequences for patients and national health service: The case of non-small cell lung cancer.
Eur J Clin Pharmacol. 2024 Apr;80(4):519-527. doi: 10.1007/s00228-024-03628-2. Epub 2024 Jan 20.
5
Reporting reimbursement price decisions for onco-hematology drugs in Spain.
Front Public Health. 2023 Oct 24;11:1265323. doi: 10.3389/fpubh.2023.1265323. eCollection 2023.
6
Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
BMJ Open. 2023 Oct 16;13(10):e066378. doi: 10.1136/bmjopen-2022-066378.
7
VOLY: The Monetary Value of a Life-Year at the End of Patients' Lives.
Appl Health Econ Health Policy. 2024 Jan;22(1):97-106. doi: 10.1007/s40258-023-00829-1. Epub 2023 Oct 4.
8
First-line tremelimumab plus durvalumab and chemotherapy chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States.
Front Pharmacol. 2023 Jul 20;14:1163381. doi: 10.3389/fphar.2023.1163381. eCollection 2023.
9
Introduction of managed entry agreements in Korea: Problem, policy, and politics.
Front Pharmacol. 2023 Apr 13;14:999220. doi: 10.3389/fphar.2023.999220. eCollection 2023.
10
Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.
Front Public Health. 2023 Feb 24;11:1109668. doi: 10.3389/fpubh.2023.1109668. eCollection 2023.
本文引用的文献
1
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.
BMJ. 2017 Oct 4;359:j4530. doi: 10.1136/bmj.j4530.
2
"Adaptive pathways" to drug authorisation: adapting to industry?
BMJ. 2016 Aug 16;354:i4437. doi: 10.1136/bmj.i4437.
3
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
Ann Oncol. 2014 Jan;25(1):107-16. doi: 10.1093/annonc/mdt523.
4
Panitumumab in combination with cytotoxic chemotherapy for the treatment of metastatic colorectal carcinoma.
Clin Colorectal Cancer. 2012 Mar;11(1):14-23. doi: 10.1016/j.clcc.2011.06.010. Epub 2011 Sep 16.
Zotero 插件